1
|
Sanchez-Moral L, Paul T, Martori C, Font-Díaz J, Sanjurjo L, Aran G, Téllez É, Blanco J, Carrillo J, Ito M, Tuttolomondo M, Ditzel HJ, Fumagalli C, Tapia G, Sidorova J, Masnou H, Fernández-Sanmartín MA, Lozano JJ, Vilaplana C, Rodriguez-Cortés A, Armengol C, Valledor AF, Kremer L, Sarrias MR. Macrophage CD5L is a target for cancer immunotherapy. EBioMedicine 2023; 91:104555. [PMID: 37054630 PMCID: PMC10139961 DOI: 10.1016/j.ebiom.2023.104555] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 03/22/2023] [Accepted: 03/23/2023] [Indexed: 04/15/2023] Open
Abstract
BACKGROUND Reprogramming of immunosuppressive tumor-associated macrophages (TAMs) presents an attractive therapeutic strategy in cancer. The aim of this study was to explore the role of macrophage CD5L protein in TAM activity and assess its potential as a therapeutic target. METHODS Monoclonal antibodies (mAbs) against recombinant CD5L were raised by subcutaneous immunization of BALB/c mice. Peripheral blood monocytes were isolated from healthy donors and stimulated with IFN/LPS, IL4, IL10, and conditioned medium (CM) from different cancer cell lines in the presence of anti-CD5L mAb or controls. Subsequently, phenotypic markers, including CD5L, were quantified by flow cytometry, IF and RT-qPCR. Macrophage CD5L protein expression was studied in 55 human papillary lung adenocarcinoma (PAC) samples by IHC and IF. Anti-CD5L mAb and isotype control were administered intraperitoneally into a syngeneic Lewis Lung Carcinoma mouse model and tumor growth was measured. Tumor microenvironment (TME) changes were determined by flow cytometry, IHC, IF, Luminex, RNAseq and RT-qPCR. FINDINGS Cancer cell lines CM induced an immunosuppressive phenotype (increase in CD163, CD206, MERTK, VEGF and CD5L) in cultured macrophages. Accordingly, high TAM expression of CD5L in PAC was associated with poor patient outcome (Log-rank (Mantel-Cox) test p = 0.02). We raised a new anti-CD5L mAb that blocked the immunosuppressive phenotype of macrophages in vitro. Its administration in vivo inhibited tumor progression of lung cancer by altering the intratumoral myeloid cell population profile and CD4+ T-cell exhaustion phenotype, thereby significantly modifying the TME and increasing the inflammatory milieu. INTERPRETATION CD5L protein plays a key function in modulating the activity of macrophages and their interactions within the TME, which supports its role as a therapeutic target in cancer immunotherapy. FUNDING For a full list of funding bodies, please see the Acknowledgements.
Collapse
Affiliation(s)
- Lidia Sanchez-Moral
- Innate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain
| | - Tony Paul
- Innate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain
| | - Clara Martori
- Innate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain; Departament de Farmacologia, Terapèutica i Toxicologia, Facultat de Veterinària, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - Joan Font-Díaz
- Department of Cell Biology, Physiology and Immunology, School of Biology, University of Barcelona and Institute of Biomedicine of the University of Barcelona (IBUB), 08028 Barcelona, Spain
| | - Lucía Sanjurjo
- Innate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain
| | - Gemma Aran
- Innate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain
| | - Érica Téllez
- Innate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain
| | - Julià Blanco
- Virology and Cellular Immunology (VIC), IrsiCaixa, 08916 Badalona, Spain
| | - Jorge Carrillo
- Virology and Cellular Immunology (VIC), IrsiCaixa, 08916 Badalona, Spain
| | - Masaoki Ito
- Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 739-8527 Hiroshima, Japan
| | - Martina Tuttolomondo
- Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark
| | - Henrik J Ditzel
- Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark; Department of Oncology, Odense University Hospital, 5220 Odense, Denmark
| | - Caterina Fumagalli
- Servicio de Anatomía Patológica, Hospital de la Santa Creu i Sant Pau, 08025, Barcelona, Spain
| | - Gustavo Tapia
- Pathology Department, Germans Trias i Pujol University Hospital (HUGTiP), 08916 Badalona, Spain
| | - Julia Sidorova
- Bioinformatics Platform, CIBERehd, 08036 Barcelona, Spain
| | - Helena Masnou
- Gastroenterology Department, Germans Trias i Pujol University Hospital (HUGTiP), 08916 Badalona, Spain; Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), 28029 Madrid, Spain
| | | | | | - Cristina Vilaplana
- Experimental Tuberculosis Unit, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain; Department of Genetics and Microbiology, Autonomous University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain; Microbiology Department, Laboratori Clínic Metropolitana Nord, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain
| | - Alhelí Rodriguez-Cortés
- Departament de Farmacologia, Terapèutica i Toxicologia, Facultat de Veterinària, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
| | - Carolina Armengol
- Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), 28029 Madrid, Spain; Childhood Liver Oncology Group, Program of Predictive and Personalized Medicine of Cancer (PMPCC), IGTP, 08916 Badalona, Spain
| | - Annabel F Valledor
- Department of Cell Biology, Physiology and Immunology, School of Biology, University of Barcelona and Institute of Biomedicine of the University of Barcelona (IBUB), 08028 Barcelona, Spain
| | - Leonor Kremer
- Protein Tools Unit and Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), 28049 Madrid, Spain
| | - Maria-Rosa Sarrias
- Innate Immunity Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain; Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), 28029 Madrid, Spain.
| |
Collapse
|
2
|
Hill-Kayser C, Yorke E, Gracia C, Keene K, Ronckers C, van Dulmen-den Broe E, Kremer L, Ginsberg J, Metzger M, Li Z, Jackson A, Constine L, Hua C. Acute Ovarian Failure and Premature Ovarian Insufficiency in Childhood Cancer Survivors Who Received Radiotherapy: A PENTEC Report. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
3
|
Labat-de-Hoz L, Comas L, Rubio-Ramos A, Casares-Arias J, Fernández-Martín L, Pantoja-Uceda D, Martín MT, Kremer L, Jiménez MA, Correas I, Alonso MA. Structure and function of the N-terminal extension of the formin INF2. Cell Mol Life Sci 2022; 79:571. [PMID: 36306014 PMCID: PMC9616786 DOI: 10.1007/s00018-022-04581-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 09/19/2022] [Accepted: 09/29/2022] [Indexed: 11/16/2022]
Abstract
In INF2—a formin linked to inherited renal and neurological disease in humans—the DID is preceded by a short N-terminal extension of unknown structure and function. INF2 activation is achieved by Ca2+-dependent association of calmodulin (CaM). Here, we show that the N-terminal extension of INF2 is organized into two α-helices, the first of which is necessary to maintain the perinuclear F-actin ring and normal cytosolic F-actin content. Biochemical assays indicated that this helix interacts directly with CaM and contains the sole CaM-binding site (CaMBS) detected in INF2. The residues W11, L14 and L18 of INF2, arranged as a 1-4-8 motif, were identified as the most important residues for the binding, W11 being the most critical of the three. This motif is conserved in vertebrate INF2 and in the human population. NMR and biochemical analyses revealed that CaM interacts directly through its C-terminal lobe with the INF2 CaMBS. Unlike control cells, INF2 KO cells lacked the perinuclear F-actin ring, had little cytosolic F-actin content, did not respond to increased Ca2+ concentrations by making more F-actin, and maintained the transcriptional cofactor MRTF predominantly in the cytoplasm. Whereas expression of intact INF2 restored all these defects, INF2 with inactivated CaMBS did not. Our study reveals the structure of the N-terminal extension, its interaction with Ca2+/CaM, and its function in INF2 activation.
Collapse
Affiliation(s)
- Leticia Labat-de-Hoz
- Centro de Biología Molecular (CBM) Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Laura Comas
- Instituto de Química Física Rocasolano (IQFR), Consejo Superior de Investigaciones Científicas, 28006, Madrid, Spain
| | - Armando Rubio-Ramos
- Centro de Biología Molecular (CBM) Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Javier Casares-Arias
- Centro de Biología Molecular (CBM) Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Laura Fernández-Martín
- Centro de Biología Molecular (CBM) Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - David Pantoja-Uceda
- Instituto de Química Física Rocasolano (IQFR), Consejo Superior de Investigaciones Científicas, 28006, Madrid, Spain
| | - M Teresa Martín
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas, 28049, Madrid, Spain
| | - Leonor Kremer
- Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas, 28049, Madrid, Spain
| | - M Angeles Jiménez
- Instituto de Química Física Rocasolano (IQFR), Consejo Superior de Investigaciones Científicas, 28006, Madrid, Spain
| | - Isabel Correas
- Centro de Biología Molecular (CBM) Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, 28049, Madrid, Spain.,Department of Molecular Biology, Universidad Autónoma de Madrid (UAM), 28049, Madrid, Spain
| | - Miguel A Alonso
- Centro de Biología Molecular (CBM) Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, 28049, Madrid, Spain.
| |
Collapse
|
4
|
Bogdan T, El Ghannudi S, Demuth S, Kremer L, De Seze J, Bigaut K. Reverse Takotsubo cardiomyopathy as a complication of MOG-antibody-associated disease (MOGAD)? A case report. Rev Neurol (Paris) 2022; 178:981-983. [DOI: 10.1016/j.neurol.2022.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 05/26/2022] [Accepted: 06/08/2022] [Indexed: 11/06/2022]
|
5
|
Chiron R, Hoefsloot W, Van Ingen J, Marchandin H, Kremer L, Morisse-Pradier H, Charriot J, Mallet JP, herrmann JL, Caimmi D, Moreau J, Dumont Y, Godreuil S, Bergeron A, Drevait M, Bouzat-Rossigneux E, Terrail N, Andrejak C, Veziris N, Grenet D, Coudrat A, Catherinot E. Amikacin Liposomal Inhalation Suspension (ALIS) in the treatment of Mycobacterium abscessus lung infection: a French observational experience. Open Forum Infect Dis 2022; 9:ofac465. [PMID: 36267258 PMCID: PMC9578164 DOI: 10.1093/ofid/ofac465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 09/08/2022] [Indexed: 11/13/2022] Open
Abstract
Background Mycobacterium abscessus infections remain difficult to manage in both cystic fibrosis (CF) and non-CF patients and reported clinical outcomes are largely unsatisfactory. Clinical trial data are limited and no approved therapies are currently available for the management of M abscessus lung diseases. As an alternative, cohort studies may provide insightful information into the management of M abscessus pulmonary disease. Methods Based on a retrospective observational cohort study, we investigated the safety and efficacy of amikacin liposome inhaled suspension (ALIS) as an adjunct to a standard antibiotic regimen for M abscessus lung infection in both CF and non-CF patients. We also assessed the association of patient drug compliance with culture conversion and clinical outcomes. Results Twenty-six patients had long-term follow-up data available. Culture conversion was achieved in 54% (14/26) of the patients with no difference between CF and non-CF patients after an average treatment duration of 10 months. Patient treatment compliance was significantly better in the converter group compared to nonconverters with an odds ratio of 44.78 associated with good compared to poor patient compliance. Overall, 9 patients (35%) experienced an adverse event that led to treatment discontinuation. Conclusions ALIS appears beneficial in both CF and non-CF populations with M abscessus lung disease.
Collapse
Affiliation(s)
- R Chiron
- HydroSciences Montpellier, CNRS, IRD, Univ Montpellier , Montpellier, FR
- University Hospital Centre Montpellier, CF center , Montpellier, FR
| | - W Hoefsloot
- Radboud University Medical Center, Pulmonary Disceases , Postbus 9101, 6500 HB, Nijmegen, NL
| | - J Van Ingen
- Radboud University Medical Centre, Department of Medical Microbiology, Geert Grooteplein Zuid 10 , Nijmegen, NL
| | - H Marchandin
- HydroSciences Montpellier, CNRS, IRD, Univ Montpellier , Montpellier, FR
- University Hospital Centre Nimes, Service de Microbiologie et Hygiène Hospitalière , Nimes, FR
| | - L Kremer
- Institut de Recherche en Infectiologie de Montpellier, INSERM, Centre National de la Recherche Scientifique UMR 9004, Univ Montpellier , Montpellier, FR
- INSERM, Institut de Recherche en Infectiologie de Montpellier , Montpellier, FR
| | | | - J Charriot
- University Hospital Centre Montpellier, Respiratory Diseases Department , Montpellier, FR
- Univ Montpellier, PhyMedExp INSERM U1046 , Montpellier, FR
| | - J P Mallet
- University Hospital Centre Montpellier, Respiratory Diseases Department , Montpellier, FR
| | - J L herrmann
- Université Paris-Saclay, Hopital Raymond Poincaré, GHU-APHP , Paris, FR
- Garches UVSQ, Inserm, Service de Microbiologie, Montigny le Bretonneux , FR
| | - D Caimmi
- University Hospital Centre Montpellier, CF center , Montpellier, FR
| | - J Moreau
- PhyMedExp, INSERM, CNRS , Montpellier, FR
- University Hospital Centre Montpellier, paediatric and respiratory departments, CF center , Montpellier, FR
| | - Y Dumont
- University Hospital Centre Montpellier, Laboratoire de bactériologie, MIVEGEC, IRD-CNRS-UM , Montpellier, FR
| | - S Godreuil
- University Hospital Centre Montpellier, Laboratoire de bactériologie, MIVEGEC, IRD-CNRS-UM , Montpellier, FR
| | - A Bergeron
- AP-HP, Hôpital Saint-Louis, Service de Pneumologie, 1 avenue Claude Vellefaux , Paris, FR
- Université Paris Diderot, Sorbonne Paris Cité, U1153 CRESS, Biostatistics and Clinical Epidemiology research team , Paris, FR
| | - M Drevait
- University Hospital Centre Montpellier, CF center , Montpellier, FR
| | - E Bouzat-Rossigneux
- Centre Hospitalier Universitaire Pointe-à-Pitre Abymes , Pointe-a-Pitre, Guadeloupe, FR
| | - N Terrail
- University Hospital Centre Montpellier, pharmacy department , Montpellier, FR
| | - C Andrejak
- CHU Amiens-Picardie, Respiratory department, Avenue Laënenc , Amiens, FR
- Amiens University, EA 4294 AGIR, Rue des Louvels , Amiens, FR
| | - N Veziris
- APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux , Paris, FR
- Sorbonne Universite, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris) , UMR 1135, Paris, FR
| | - D Grenet
- Hopital Foch, Pneumologie et Transplantation Pulmonaire , Suresnes, FR
| | - A Coudrat
- University Hospital Centre Montpellier, CF center , Montpellier, FR
| | - E Catherinot
- Hôpital Foch, pneumology department , Suresnes, FR
| |
Collapse
|
6
|
Gebauer J, Skinner R, Haupt R, Kremer L, van der Pal H, Michel G, Armstrong GT, Hudson MM, Hjorth L, Lehnert H, Langer T. The chance of transition: strategies for multidisciplinary collaboration. Endocr Connect 2022; 11:e220083. [PMID: 35900792 PMCID: PMC9422248 DOI: 10.1530/ec-22-0083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Accepted: 07/13/2022] [Indexed: 11/08/2022]
Abstract
Many long-term childhood cancer survivors suffer from treatment-related late effects, which may occur in any organ and include a wide spectrum of conditions. Long-term follow-up (LTFU) is recommended to facilitate early diagnosis and to ensure better health outcomes. Due to the heterogeneity of these sequelae, different specialists work together in the diagnosis and treatment of these conditions. Experts from both pediatric and internal medicine are involved in age-appropriate care by providing a transition process. Hence, LTFU of childhood cancer survivors is a prototypic example of multidisciplinary care for patients with complex needs treated in a specialized setting. International collaborations of healthcare professionals and scientists involved in LTFU of childhood cancer survivors, such as the International Guideline Harmonization Group, compile surveillance recommendations that can be clinically adopted all over the world. These global networks of clinicians and researchers make a joint effort to address gaps in knowledge, increase visibility and awareness of cancer survivorship and provide an excellent example of how progress in clinical care and scientific research may be achieved by international and multidisciplinary collaboration.
Collapse
Affiliation(s)
- J Gebauer
- Department of Internal Medicine I, University Hospital of Schleswig-Holstein, Campus Luebeck and Institute for Endocrinology and Diabetes, University of Luebeck, Luebeck, Germany
| | - R Skinner
- Department of Paediatric and Adolescent Haematology and Oncology and Children’s BMT Unit, Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK
| | - R Haupt
- DOPO Clinic, Department of Hematology/Oncolgy, IRCCS Istituto Giannina Gaslini, Genova, Italy
| | - L Kremer
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- Amsterdam UMC, Emma’s Children’s Hospital, Amsterdam, The Netherlands
| | - H van der Pal
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - G Michel
- Department of Health Sciences and Medicine, University of Lucerne, Luzern, Switzerland
| | - G T Armstrong
- Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
| | - M M Hudson
- Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
| | - L Hjorth
- Department of Clinical Sciences Lund, Paediatrics, Lund University, Skane University Hospital, Lund, Sweden
| | - H Lehnert
- Paris Lodron University of Salzburg, Salzburg, Austria
| | - T Langer
- Pediatric Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
| |
Collapse
|
7
|
Santamaria S, Delgado M, Botas M, Castellano E, Corraliza-Gorjon I, Lafuente P, Muñoz-Calleja C, Toribio M, Kremer L, Garcia-Sanz JA. Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors. Front Immunol 2022; 13:825635. [PMID: 35967322 PMCID: PMC9363564 DOI: 10.3389/fimmu.2022.825635] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Accepted: 07/07/2022] [Indexed: 11/13/2022] Open
Abstract
Relapsed or refractory T acute lymphoblastic leukemia (T-ALL) still carries poor prognosis. Aiming to improve outcomes, the therapeutic potential of an anti-CCR9 monoclonal antibody (mAb 92R), targeting the human chemokine-receptor CCR9 is analyzed on orthotopic xenotransplants. 92R mAb treatment of mice carrying human CCR9+ T-ALL cell lines or primary T cell leukemias inhibits tumor growth and increases survival. The therapeutic effects of 92R are specific and synergize with chemotherapeutic agents increasing survival. Furthermore, 92R decreases size of non-hematopoietic tumors with a forced CCR9 expression and of solid tumors generated by the pancreatic adenocarcinoma cell line AsPC-1. In addition, a humanized version of 92R mAb (Srb1) is also able to inhibit growth of CCR9+ T-ALL tumor cells in vivo, increasing survival 2.66-fold. Finally, 92R mAb prevents liver accumulation of infiltrates and reduces tumor cell numbers in already formed infiltrates. Thus, the humanized version of 92R mAb (Srb1), displays therapeutic potential for CCR9+ tumor treatment and might represent one of the first therapeutic antibodies for precision medicine on T-ALL patients.
Collapse
Affiliation(s)
- Silvia Santamaria
- Centro de Investigaciones Biologicas Margarita Salas (CIB-CSIC), Department of Molecular Medicine, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Marisa Delgado
- Centro de Investigaciones Biologicas Margarita Salas (CIB-CSIC), Department of Molecular Medicine, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Marta Botas
- Centro de Investigaciones Biologicas Margarita Salas (CIB-CSIC), Department of Molecular Medicine, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Eva Castellano
- Centro de Investigaciones Biologicas Margarita Salas (CIB-CSIC), Department of Molecular Medicine, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Isabel Corraliza-Gorjon
- Centro Nacional de Biotecnología (CNB-CSIC), Department of Immunology and Oncology, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Paloma Lafuente
- Centro de Investigaciones Biologicas Margarita Salas (CIB-CSIC), Department of Molecular Medicine, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Cecilia Muñoz-Calleja
- Servicio de Inmunología, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain
| | - Maria L. Toribio
- Centro de Biología Molecular Severo Ochoa (CBMSO-CSIC-UAM), Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Leonor Kremer
- Centro Nacional de Biotecnología (CNB-CSIC), Department of Immunology and Oncology, Consejo Superior de Investigaciones Científicas, Madrid, Spain
- *Correspondence: Jose A. Garcia-Sanz, ; Leonor Kremer,
| | - Jose A. Garcia-Sanz
- Centro de Investigaciones Biologicas Margarita Salas (CIB-CSIC), Department of Molecular Medicine, Consejo Superior de Investigaciones Científicas, Madrid, Spain
- *Correspondence: Jose A. Garcia-Sanz, ; Leonor Kremer,
| |
Collapse
|
8
|
van der Kooi A, van Dijk M, Broer L, van den Berg M, Laven J, van Leeuwen F, Ronckers C, van der Heiden-van der Loo M, Hudson M, Byrne J, Pluijm S, Spix C, Kaatsch P, Kremer L, Yasui Y, Brooke J, Uitterlinden A, van den Heuvel-Eibrink M, van Dulmen-den Broeder E. 072 Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function. Eur J Obstet Gynecol Reprod Biol 2022. [DOI: 10.1016/j.ejogrb.2022.02.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Rubio-Ramos A, Bernabé-Rubio M, Labat-de-Hoz L, Casares-Arias J, Kremer L, Correas I, Alonso MA. MALL, a membrane-tetra-spanning proteolipid overexpressed in cancer, is present in membraneless nuclear biomolecular condensates. Cell Mol Life Sci 2022; 79:236. [PMID: 35399121 PMCID: PMC8995265 DOI: 10.1007/s00018-022-04270-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 03/08/2022] [Accepted: 03/22/2022] [Indexed: 12/04/2022]
Abstract
Proteolipids are proteins with unusual lipid-like properties. It has long been established that PLP and plasmolipin, which are two unrelated membrane-tetra-spanning myelin proteolipids, can be converted in vitro into a water-soluble form with a distinct conformation, raising the question of whether these, or other similar proteolipids, can adopt two different conformations in the cell to adapt their structure to distinct environments. Here, we show that MALL, another proteolipid with a membrane-tetra-spanning structure, distributes in membranes outside the nucleus and, within the nucleus, in membrane-less, liquid-like PML body biomolecular condensates. Detection of MALL in one or other environment was strictly dependent on the method of cell fixation used, suggesting that MALL adopts different conformations depending on its physical environment —lipidic or aqueous— in the cell. The acquisition of the condensate-compatible conformation requires PML expression. Excess MALL perturbed the distribution of the inner nuclear membrane proteins emerin and LAP2β, and that of the DNA-binding protein BAF, leading to the formation of aberrant nuclei. This effect, which is consistent with studies identifying overexpressed MALL as an unfavorable prognostic factor in cancer, could contribute to cell malignancy. Our study establishes a link between proteolipids, membranes and biomolecular condensates, with potential biomedical implications.
Collapse
Affiliation(s)
- Armando Rubio-Ramos
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Miguel Bernabé-Rubio
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Leticia Labat-de-Hoz
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Javier Casares-Arias
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Leonor Kremer
- Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, 28049, Madrid, Spain
| | - Isabel Correas
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049, Madrid, Spain
- Department of Molecular Biology, Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Miguel A Alonso
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 28049, Madrid, Spain.
| |
Collapse
|
10
|
Nestler T, Kremer L, Von Brandenstein M, Wittersheim M, Wagener-Ryczek S, Paffenholz P, Mueller S, Quaas A, Hellmich M, Odenthal M, Pfister D, Heidenreich A. Differentially expressed mRNA/proteins can distinguish viable germ cell tumors and teratomas from necrosis in retroperitoneal lymph node resections after chemotherapy (pcRPLND). Eur Urol 2022. [DOI: 10.1016/s0302-2838(22)00643-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Bigaut K, Kremer L, Fleury M, Lanotte L, Collongues N, de Seze J. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection. Rev Neurol (Paris) 2021; 177:1237-1240. [PMID: 34172292 PMCID: PMC8206590 DOI: 10.1016/j.neurol.2021.05.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 05/22/2021] [Accepted: 05/26/2021] [Indexed: 01/07/2023]
Abstract
Objective To analyze the humoral response after COVID-19 vaccination in patients with multiple sclerosis (MS) according to disease-modifying treatments (DMTs) and in comparison with the humoral response after SARS-CoV-2 infection. Methods We included 28 MS patients with serological results after COVID-19 vaccination (Pfizer-BioNTech or Moderna ARNm) and 61 MS patients with serological results after COVID-19 (COVID-19 group) among patients followed up at the MS Center of Strasbourg, France, between January and April 2021. The primary endpoint was the IgG index according to DMTs (anti-CD20 mAb, sphingosine 1-phosphate receptor [S1PR] modulator and other treatments) and COVID-19 vaccine or COVID-19 groups. Results In the vaccinated MS patients, the median IgG index was lower in patients treated with anti-CD20 mAb and in patients treated with S1PR modulator compared to patients receiving other or no DMTs (4.80 [1.58–28.6], 16.5 [16.3–48.5], 1116 [434–1747] and 1272 [658–1886], respectively, P < 0.001). Similar results were found for MS patients after COVID-19. Conclusions Patients with MS and treated with S1PR modulators or anti-CD20 mAb had a reduced humoral response after COVID-19 vaccine.
Collapse
Affiliation(s)
- K Bigaut
- Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France; Clinical Investigation Center, hôpitaux universitaires de Strasbourg, Strasbourg, France.
| | - L Kremer
- Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France; Clinical Investigation Center, hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - M Fleury
- Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France
| | - L Lanotte
- Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France; Clinical Investigation Center, hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - N Collongues
- Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France; Clinical Investigation Center, hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - J de Seze
- Department of Neurology, hôpitaux universitaires de Strasbourg, 1, avenue Molière, 67200 Strasbourg, France; Clinical Investigation Center, hôpitaux universitaires de Strasbourg, Strasbourg, France
| |
Collapse
|
12
|
Lersy F, Noblet V, Willaume T, Collongues N, Kremer L, Fleury M, de Seze J, Kremer S. Identification and measurement of cervical spinal cord atrophy in neuromyelitis optica spectrum disorders (NMOSD) and correlation with clinical characteristics and cervical spinal cord MRI data. Rev Neurol (Paris) 2020; 177:85-92. [PMID: 32753321 DOI: 10.1016/j.neurol.2020.05.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Revised: 05/10/2020] [Accepted: 05/11/2020] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The spinal cord is one of the two main targets of neuromyelitis optica (NMO). The aim of this study was to highlight cervical spinal cord atrophy in NMO patients as compared to controls and to assess correlations between atrophy and clinical characteristics and cervical spinal cord MRI data. METHODS This prospective study investigated 15 patients with a diagnosis of NMOSD and 15 healthy controls. The whole cervical spinal cord was explored by MRI. The cross-sectional area (CSA) was estimate at every level of cup. This measurement was then averaged on the whole cervical spinal cord, providing a single measurement for every subject, denoted as mean CSA. RESULTS Mean CSA was 68.5 mm2 in the population of NMO patients and 72.8 mm2 in the population of healthy subjects. NMO patients had significantly smaller cervical spinal cord area than healthy controls (T test=0.009). Cervical spinal cord atrophy was associated with clinical signs of medullary involvement (T test=0.0006). There was a tendency toward a relation between cervical spinal cord atrophy and the Expanded Disability Status Scale (EDSS) (T test=0.07). This correlation seems statistically significant (T test<0.05) at the level of the upper cervical spinal cord (C2-C3) CONCLUSION: This study provides the first evidence of cervical spinal cord atrophy in NMOSD by studying the entire cervical spinal cord. Upper cervical spinal cord atrophy was substantially correlated to clinical disability and seems more involved in the development of clinical disability in NMOSD patients in comparison to the lower cervical spinal cord.
Collapse
Affiliation(s)
- F Lersy
- University hospital of Strasboug, France.
| | - V Noblet
- University hospital of Strasboug, France
| | - T Willaume
- University hospital of Strasboug, France
| | | | - L Kremer
- University hospital of Strasboug, France
| | - M Fleury
- University hospital of Strasboug, France
| | - J de Seze
- University hospital of Strasboug, France
| | - S Kremer
- University hospital of Strasboug, France
| |
Collapse
|
13
|
Bigaut K, Lambert C, Kremer L, Lebrun C, Cohen M, Ciron J, Bourre B, Créange A, Kerschen P, Montcuquet A, Carra-Dalliere C, Ayrignac X, Labauge P, de Seze J, Collongues N. Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. Mult Scler 2020; 27:232-238. [DOI: 10.1177/1352458520906995] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: Atypical myelitis in multiple sclerosis (MS) is characterized by extensive myelitis in the longitudinal (longitudinally extensive transverse myelitis) or axial plane (transverse myelitis). Objective: To characterize a cohort of MS patients with atypical myelitis. Methods: Atypical myelitis was extracted from the French and Luxembourg MS databases and compared to two cohorts of MS patients with typical myelitis and neuromyelitis optica spectrum disorders (NMOSDs) patients with myelitis. Results: We enrolled 28 MS patients with atypical myelitis, 68 MS patients with typical myelitis and 119 NMOSD patients with a first episode of myelitis. MS patients with atypical myelitis were characterized by a mean age of 34.0 (±10.7) years and 64.3% were women. In 82.1% of the patients, atypical myelitis was the first episode of MS. Mean Expanded Disability Status Scale (EDSS) scores at nadir and 3–6 months after onset were 4.1 ± 2.1 and 3.3 ± 2, respectively. Differences between groups revealed a predominance of cervicothoracic myelitis and a higher level of disability in NMOSD patients. Disability in MS patients with atypical myelitis was more severe than in the MS patients with typical myelitis; 28% had already converted to progressive MS within our mean follow-up of 39.6 (±30.4) months. Conclusion: Atypical myelitis may be the first presentation of MS and is associated with poorer prognosis.
Collapse
Affiliation(s)
- K Bigaut
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - C Lambert
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - L Kremer
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - C Lebrun
- CRC-SEP, Neurologie, Université Nice Côte d’Azur, CHU Pasteur 2, Nice, France
| | - M Cohen
- CRC-SEP, Neurologie, Université Nice Côte d’Azur, CHU Pasteur 2, Nice, France
| | - J Ciron
- CRC-SEP, Neurologie, CHU Toulouse, Toulouse, France
| | - B Bourre
- Service de Neurologie, CHU de Rouen, Rouen, France
| | - A Créange
- Service de Neurologie, CHU de Créteil, Paris, France
| | - P Kerschen
- Service de Neurologie, Centre Hospitalier de Luxembourg, Luxembourg
| | - A Montcuquet
- Service de Neurologie, CHU de Limoges, Limoges, France
| | | | - X Ayrignac
- CRC-SEP, Neurologie, CHU de Montpellier, Montpellier, France
| | - P Labauge
- CRC-SEP, Neurologie, CHU de Montpellier, Montpellier, France
| | - J de Seze
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| | - N Collongues
- CRC-SEP, Neurologie, Hôpital de Hautepierre, Strasbourg, France
| |
Collapse
|
14
|
Vogelius I, Vargo J, Ronckers C, Yorke E, Kremer L, Chafe S, van Santen H, Bentzen S, Constine L, Milano M. Hypothyroidism (HT) after Radiotherapy (RT) in Children: Initial Results of Thyroid Gland Dose-Response Relationship from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Initiative. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Bates J, Keshavarz H, Rancati T, Gagliardi G, Aznar M, Moiseenko V, Yorke E, Armenian S, Kremer L, Chen M, van der Pal H, Cutter D, Constine L, Hodgson D. Cardiac Disease in Childhood Cancer Survivors Treated with Radiotherapy: Final Results from the PENTEC Group. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
16
|
Kolia-Diafouka P, Carrère-Kremer S, Lounnas M, Bourdin A, Kremer L, Van de Perre P, Godreuil S, Tuaillon E. Detection of Mycobacterium tuberculosis in paucibacillary sputum: performances of the Xpert MTB/RIF ultra compared to the Xpert MTB/RIF, and IS6110 PCR. Diagn Microbiol Infect Dis 2019; 94:365-370. [DOI: 10.1016/j.diagmicrobio.2019.02.008] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 02/05/2019] [Accepted: 02/06/2019] [Indexed: 12/20/2022]
|
17
|
Perez-Zsolt D, Erkizia I, Pino M, García-Gallo M, Martin MT, Benet S, Chojnacki J, Fernández-Figueras MT, Guerrero D, Urrea V, Muñiz-Trabudua X, Kremer L, Martinez-Picado J, Izquierdo-Useros N. Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. Nat Microbiol 2019; 4:1558-1570. [PMID: 31160823 DOI: 10.1038/s41564-019-0453-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Accepted: 04/11/2019] [Indexed: 12/14/2022]
Abstract
Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.
Collapse
Affiliation(s)
- Daniel Perez-Zsolt
- IrsiCaixa AIDS Research Institute, Badalona, Spain.,Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - Maria Pino
- IrsiCaixa AIDS Research Institute, Badalona, Spain
| | - Mónica García-Gallo
- Protein Tools Unit and Department of Immunology and Oncology, Spanish National Center for Biotechnology, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Maria Teresa Martin
- Protein Tools Unit and Department of Immunology and Oncology, Spanish National Center for Biotechnology, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Susana Benet
- IrsiCaixa AIDS Research Institute, Badalona, Spain.,Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - María Teresa Fernández-Figueras
- Department of Pathology, Hospital Universitari General de Catalunya-Grupo Quirón Salud, Barcelona, Spain.,Universitat Internacional de Catalunya, Barcelona, Spain.,Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain
| | - Dolores Guerrero
- Otorhinolaryngology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Victor Urrea
- IrsiCaixa AIDS Research Institute, Badalona, Spain
| | - Xabier Muñiz-Trabudua
- IrsiCaixa AIDS Research Institute, Badalona, Spain.,Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Leonor Kremer
- Protein Tools Unit and Department of Immunology and Oncology, Spanish National Center for Biotechnology, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Javier Martinez-Picado
- IrsiCaixa AIDS Research Institute, Badalona, Spain. .,University of Vic-Central University of Catalonia, Vic, Spain. .,Catalan Institution for Research and Advanced Studies, Barcelona, Spain.
| | - Nuria Izquierdo-Useros
- IrsiCaixa AIDS Research Institute, Badalona, Spain. .,Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain.
| |
Collapse
|
18
|
Lebrun C, Vukusic S, Abadie V, Achour C, Ader F, Alchaar H, Alkhedr A, Andreux F, Androdias G, Arjmand R, Audoin B, Audry D, Aufauvre D, Autreaux C, Ayrignac X, Bailbe M, Benazet M, Bensa C, Bensmail D, Berger E, Bernady P, Bertagna Y, Biotti D, Blanchard-Dauphin A, Bonenfant J, Bonnan M, Bonnemain B, Borgel F, Botelho-Nevers E, Boucly S, Bourre B, Boutière C, Branger P, Brassat D, Bresch S, Breuil V, Brochet B, Brugeilles H, Bugnon P, Cabre P, Camdessanché JP, Carra-Dalière C, Casez O, Chamouard JM, Chassande B, Chataignier P, Chbicheb M, Chenet A, Ciron J, Clavelou P, Cohen M, Colamarino R, Collongues N, Coman I, Corail PR, Courtois S, Coustans M, Creange A, Creisson E, Daluzeau N, Davenas C, De Seze J, Debouverie M, Depaz R, Derache N, Divio L, Douay X, Dulau C, Durand-Dubief F, Edan G, Elias Z, Fagniez O, Faucher M, Faucheux JM, Fournier M, Gagneux-Brunon A, Gaida P, Galli P, Gallien P, Gaudelus J, Gault D, Gayou A, Genevray M, Gentil A, Gere J, Gignoux L, Giroux M, Givron P, Gout O, Grimaud J, Guennoc AM, Hadhoum N, Hautecoeur P, Heinzlef O, Jaeger M, Jeannin S, Kremer L, Kwiatkowski A, Labauge P, Labeyrie C, Lachaud S, Laffont I, Lanctin-Garcia C, Lannoy J, Lanotte L, Laplaud D, Latombe D, Lauxerois M, Le Page E, Lebrun-Frenay C, Lejeune P, Lejoyeux P, Lemonnier B, Leray E, Loche CM, Louapre C, Lubetzki C, Maarouf A, Mada B, Magy L, Maillart E, Manchon E, Marignier R, Marque P, Mathey G, Maurousset A, Mekies C, Merienne M, Michel L, Milor AM, Moisset X, Montcuquet A, Moreau T, Morel N, Moussa M, Naudillon JP, Normand M, Olive P, Ouallet JC, Outteryck O, Pacault C, Papeix C, Patry I, Peaureaux D, Pelletier J, Pichon B, Pittion S, Planque E, Pouget MC, Pourcher V, Radot C, Robert I, Rocher F, Ruet A, Ruet A, Saint-Val C, Salle JY, Salmon A, Sartori E, Schaeffer S, Stankhof B, Taithe F, Thouvenot E, Tizon C, Tourbah A, Tourniaire P, Vaillant M, Vermersch P, Vidil S, Wahab A, Warter MH, Wiertlewski S, Wiplosz B, Wittwer B, Zaenker C, Zephir H. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris) 2019; 175:341-357. [DOI: 10.1016/j.neurol.2019.04.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Revised: 03/31/2019] [Accepted: 04/11/2019] [Indexed: 10/26/2022]
|
19
|
Vila-Caballer M, González-Granado JM, Zorita V, Abu Nabah YN, Silvestre-Roig C, Del Monte-Monge A, Molina-Sánchez P, Ait-Oufella H, Andrés-Manzano MJ, Sanz MJ, Weber C, Kremer L, Gutiérrez J, Mallat Z, Andrés V. Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice. J Mol Cell Cardiol 2019; 132:154-163. [PMID: 31121182 DOI: 10.1016/j.yjmcc.2019.05.009] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 05/12/2019] [Indexed: 12/23/2022]
Abstract
The CC chemokine 1 (CCL1, also called I-309 or TCA3) is a potent chemoattractant for leukocytes that plays an important role in inflammatory processes and diseases through binding to its receptor CCR8. Here, we investigated the role of the CCL1-CCR8 axis in atherosclerosis. We found increased expression of CCL1 in the aortas of atherosclerosis-prone fat-fed apolipoprotein E (Apoe)-null mice; moreover, in vitro flow chamber assays and in vivo intravital microscopy demonstrated an essential role for CCL1 in leukocyte recruitment. Mice doubly deficient for CCL1 and Apoe exhibited enhanced atherosclerosis in aorta, which was associated with reduced plasma levels of the anti-inflammatory interleukin 10, an increased splenocyte Th1/Th2 ratio, and a reduced regulatory T cell (Treg) content in aorta and spleen. Reduced Treg recruitment and aggravated atherosclerosis were also detected in the aortas of fat-fed low-density lipoprotein receptor-null mice treated with CCR8 blocking antibodies. These findings demonstrate that disruption of the CCL1-CCR8 axis promotes atherosclerosis by inhibiting interleukin 10 production and Treg recruitment and function.
Collapse
Affiliation(s)
- Marian Vila-Caballer
- Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain; Universidad Cardenal Herrera-CEU (CEU Universities), Valencia, Spain
| | - José M González-Granado
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBER-CV), Spain; LamImSys Laboratory, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Virginia Zorita
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Yafa N Abu Nabah
- Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain
| | - Carlos Silvestre-Roig
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany
| | - Alberto Del Monte-Monge
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBER-CV), Spain
| | | | - Hafid Ait-Oufella
- Institut National de la Santé et de la Recherche Médicale (INSERM), Paris Cardiovascular Research Center, Paris, France
| | - María J Andrés-Manzano
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBER-CV), Spain
| | - María J Sanz
- Departamento de Farmacología, Universidad de Valencia and Instituto de Investigación Sanitaria-INCLIVA, Valencia, Spain
| | - Christian Weber
- Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian University, Munich, Germany
| | - Leonor Kremer
- Departamento de Inmunología y Oncología, Centro Nacional de Biotecnología-CSIC, Madrid, Spain
| | - Julio Gutiérrez
- Departamento de Inmunología y Oncología, Centro Nacional de Biotecnología-CSIC, Madrid, Spain
| | - Ziad Mallat
- Institut National de la Santé et de la Recherche Médicale (INSERM), Paris Cardiovascular Research Center, Paris, France; Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Vicente Andrés
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBER de Enfermedades Cardiovasculares (CIBER-CV), Spain.
| |
Collapse
|
20
|
Bárcena C, Aran G, Perea L, Sanjurjo L, Téllez É, Oncins A, Masnou H, Serra I, García-Gallo M, Kremer L, Sala M, Armengol C, Sancho-Bru P, Sarrias MR. CD5L is a pleiotropic player in liver fibrosis controlling damage, fibrosis and immune cell content. EBioMedicine 2019; 43:513-524. [PMID: 31076347 PMCID: PMC6558273 DOI: 10.1016/j.ebiom.2019.04.052] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Revised: 04/17/2019] [Accepted: 04/26/2019] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Chronic hepatic inflammation leads to liver fibrosis, which may progress to cirrhosis, a condition with high morbidity. Our aim was to assess the as yet unknown role of innate immunity protein CD5L in liver fibrosis. METHODS CD5L was measured by ELISA in plasma samples from cirrhotic (n = 63) and hepatitis (n = 39) patients, and healthy controls (n = 7), by immunohistochemistry in cirrhotic tissue (n = 12), and by quantitative RT-PCR in mouse liver cell subsets isolated by cell sorting. Recombinant CD5L (rCD5L) was administered into a murine model of CCl4-induced fibrosis, and damage, fibrosis and hepatic immune cell infiltration, including the LyC6hi (pro-fibrotic)-LyC6low (pro-resolutive) monocyte ratio were determined. Moreover, rCD5L was added into primary human hepatic stellate cells to study transforming growth factor β (TGFβ) activation responses. FINDINGS Cirrhotic patients showed elevated plasma CD5L concentrations as compared to patients with hepatitis and healthy controls (Mann-Whitney test p < 0·0001). Moreover, plasma CD5L correlated with disease progression, FIB4 fibrosis score (r:0·25, p < 0·0001) and tissue expression (r = 0·649; p = 0·022). Accordingly, CCl4-induced damage increased CD5L levels in total liver, particularly in hepatocytes and macrophages. rCD5L administration attenuated CCl4-induced injury and fibrosis as determined by reduced serum transaminase and collagen content. Moreover, rCD5L inhibited immune cell infiltration and promoted a phenotypic shift in monocytes from LyC6hi to LyC6low. Interestingly, rCD5L also had a direct effect on primary human hepatic stellate cells promoting SMAD7 expression, thus repressing TGFβ signalling. INTERPRETATION Our study identifies CD5L as a key pleiotropic inhibitor of chronic liver injury. FUND: Fundació Marató TV3, AGAUR and the ISCIII-EDRF.
Collapse
Affiliation(s)
- Cristina Bárcena
- Innate Immunity Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Gemma Aran
- Innate Immunity Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Luís Perea
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Lucía Sanjurjo
- Innate Immunity Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain; Network for Biomedical Research in Diabetes and Associated Metabolic Disorders (CIBERDEM), Spain
| | - Érica Téllez
- Innate Immunity Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Anna Oncins
- Innate Immunity Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Helena Masnou
- Gastroenterology Dept., University Hospital Germans Trias i Pujol (HUGTiP), Badalona, Spain
| | - Isabel Serra
- Gastroenterology Dept., University Hospital Germans Trias i Pujol (HUGTiP), Badalona, Spain
| | - Mónica García-Gallo
- Protein Tools Unit and Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| | - Leonor Kremer
- Protein Tools Unit and Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| | - Margarita Sala
- Gastroenterology Dept., University Hospital Germans Trias i Pujol (HUGTiP), Badalona, Spain; Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Spain
| | - Carolina Armengol
- Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Spain; Childhood Liver Oncology Group, Program of Predictive and Personalized Medicine of Cancer (PMPCC), IGTP, Spain
| | - Pau Sancho-Bru
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Spain
| | - Maria-Rosa Sarrias
- Innate Immunity Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain; Network for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd), Spain.
| |
Collapse
|
21
|
Bigaut K, Kremer L, Hacquard A, Collongues N, De Seze J. Miller Fisher syndrome mimicking botulism: Clinical and pathophysiological discussion of a case. Rev Neurol (Paris) 2019; 175:403-405. [PMID: 31047688 DOI: 10.1016/j.neurol.2018.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2018] [Revised: 06/21/2018] [Accepted: 06/26/2018] [Indexed: 11/26/2022]
Affiliation(s)
- K Bigaut
- Service de neurologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France.
| | - L Kremer
- Service de neurologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1434, centre d'investigation clinique, 67000 Strasbourg, France
| | - A Hacquard
- Service de neurologie, groupe hospitalier de la région Mulhouse sud-Alsace, 68100 Mulhouse, France
| | - N Collongues
- Service de neurologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1434, centre d'investigation clinique, 67000 Strasbourg, France; Inserm U1119, biopathologie de la myéline, neuroprotection et stratégies thérapeutiques, fédération de médecine translationnelle de Strasbourg, 67000 Strasbourg, France
| | - J De Seze
- Service de neurologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France; Inserm U1434, centre d'investigation clinique, 67000 Strasbourg, France; Inserm U1119, biopathologie de la myéline, neuroprotection et stratégies thérapeutiques, fédération de médecine translationnelle de Strasbourg, 67000 Strasbourg, France
| |
Collapse
|
22
|
Bigaut K, Kremer L, Hacquard A, Wolff B, Collongues N, De Seze J. A case of acute posterior multifocal placoid pigment epitheliopathy with aseptic meningitis and cerebral infarction. Rev Neurol (Paris) 2019; 175:329-331. [DOI: 10.1016/j.neurol.2018.06.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 06/19/2018] [Accepted: 06/20/2018] [Indexed: 11/28/2022]
|
23
|
van Ommen C, Iersel L, Lequin M, Janssens G, Clement S, Boot A, Caron H, Claahsen-van der Grinten H, Granzen B, Han K, Michiels E, van Trotsenburg A, Vandertop W, van Vuurden D, Kremer L, Schouten-van Meeteren A, van Santen H. MON-458 Radiological Alterations Of The Hypothalamic-pituitary Region After Craniospinal Irradiation For Medulloblastoma During Childhood. J Endocr Soc 2019. [PMCID: PMC6550906 DOI: 10.1210/js.2019-mon-458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Background Hypothalamic-pituitary (HP) dysfunction after craniospinal irradiation (CSI) is frequently observed in childhood brain tumor survivors (CBTS). The risk increases with higher dose and younger age at time of radiation exposure. Whether radiological alterations of the HP-region or alterations in brain volume are predictive of HP dysfunction remains unknown. Aim The aim of this (retrospective) study was to quantify radiological alterations of the HP-region in time in CBTS after CSI and to correlate these alterations to the occurrence of HP dysfunction. Methods Ninety survivors of childhood medulloblastoma (mean age at diagnosis: 8.3 years) from a previously reported nationwide cohort, treated with CSI between 2002-2012, were included. Sixty CBTS (67%) were diagnosed with HP dysfunction during follow-up (FU). All MRI scans were collected from time of diagnosis, post-neurosurgical intervention, post-radiation and 3 and 5 years of FU. Pituitary height (PH) and width (PW) were measured on mid-sagittal images. The pituitary stalk (PS) width was assessed by measuring the ratio of the PS to basilar artery (BA) on axial images on the same plane in the middle of the PS. Volume measurements of the PG (PGV) were performed. Observers were blinded for outcome of HP function. Separate analyses were performed for children < 6 years at time of CSI. All measurements were corrected for age and gender using Z-scores. Statistical analyses were performed by SPSS (General Linear Model repeated measures with Bonferroni correction). Results Mean PH (p<0.01, 95% CI [0.25, 1.27], PW (p<0.01, 95% CI [0.85-2.32], width of the PS (p<0.01, 95% CI [0.38-3.0] and PGV (p<0.05, 95% CI [0.12-1.29] declined during FU. No correlation was observed between radiological alterations in time and the presence of HP dysfunction. On a marginal trend level, an interaction effect was seen for PS/BA ratio and the presence of HP dysfunction (p= 0.097, F= 2.44). HP dysfunction occurred more frequently in CBTS treated with CSI < 6 years (71% vs 58%). Radiological alterations in this age group could also not be related to occurrence of HP dysfunction. Conclusion When compared to age and gender reference values, CBTS treated with CSI show radiological alterations of the HP region in time. Exposure to cranial irradiation in childhood seems to have a negative effect on PH, PW, width of PS and PGV. However, these effects cannot be related to the development of HP dysfunction or age at time of CRT. Prospective studies are needed to confirm these results, with systematic evaluation of the HP function in time.
Collapse
Affiliation(s)
- Corinde van Ommen
- Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, , Netherlands
| | - Laura Iersel
- Pediatric Endocrinology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, , Netherlands
| | - Maarten Lequin
- Department of Radiology, University Medical Center Utrecht, Utrecht, , Netherlands
| | - Geert Janssens
- Department of Radiation Oncology, Princess Maxima Center & UMCU, Utrecht, , Netherlands
| | - Sarah Clement
- Amsterdam University Medical Centres, Amsterdam, , Netherlands
| | - Annemieke Boot
- paediatrics, University Medical Center Groningen, Groningen, , Netherlands
| | - Huib Caron
- Amsterdam University Medical Centres, Amsterdam, , Netherlands
| | | | - B Granzen
- Pediatric Oncology, Maastricht University Medical Center, Maastricht, , Netherlands
| | - K. Han
- Department of Neurosurgery, University Medical Center Utrecht, Utrecht, , Netherlands
| | - E. Michiels
- Pediatric Oncology, Erasmus University Medical Center - Sophia Children’s Hospital, Rotterdam, , Netherlands
| | | | - W Vandertop
- Amsterdam University Medical Centres, Amsterdam, , Netherlands
| | - D van Vuurden
- Amsterdam University Medical Centres, Amsterdam, , Netherlands
| | - L. Kremer
- Amsterdam University Medical Centres, Amsterdam, , Netherlands
| | | | - H van Santen
- Pediatric Endocrinology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, , Netherlands
| |
Collapse
|
24
|
Lo A, Ronckers C, van Dijk I, Rancati T, Avanzo M, Gagliardi G, Kremer L, Constine L, Marcus K. Risks of Breast Hypoplasia and Decreased Lactation from Radiation Therapy (RT) in Survivors of Pediatric Malignancy: Results from the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Initiative. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
25
|
Hill-Kayser C, Hua C, Yorke E, Keene K, Ronckers C, van Dulmen-den Broe E, Kremer L, Gracia C, Ginsberg J, Metzger M, Constine L. Ovarian Toxicity in Pediatric Cancer Survivors after Abdominopelvic Radiation Therapy: A Report From the PENTEC (Pediatric Normal Tissue Effects in the Clinic) Initiative. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Esiashvili N, Nanda R, Ronckers C, Kremer L, Eaton B, Constine L, Wasilewski-Masker K, Kaste S, Hua C. Risk of Kyphoscoliosis in Pediatric Patients Receiving Radiation Therapy: Results from the Musculoskeletal Task Force of the Pediatric Normal Tissue Effects in the Clinic (PENTEC) Initiative. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.1347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Abstract
The treatment of pediatric patients in trauma surgery is a special situation in every aspect. For deciding on the correct treatment of fractures of the lower leg and ankle joint, various parameters, such as residual growth rate, skeletal age and height of the patient are decisive. The differences between fractures in children and adolescents are the open epiphyseal plate and the resulting residual growth. The bones of young children have a higher healing tendency and a greater potential for correction than in adolescents. Especially in the lower leg and the ankle joint, the potential for correction is decisive for the healing of fractures and for possible development of growth disorders. The limits of tolerance concerning axial malalignments and the expected spontaneous potential for correction must play an essential role for further treatment with conservative or operative therapy. This article deals with the special features of pediatric fractures of the lower leg and ankle joint.
Collapse
Affiliation(s)
- M Voth
- Universitätsklinikum Frankfurt, Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland.
| | - L Kremer
- Universitätsklinikum Frankfurt, Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland
| | - I Marzi
- Universitätsklinikum Frankfurt, Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland
| |
Collapse
|
28
|
Dormegny L, Chibbaro S, Ganau M, Santin M, Kremer L, Proust F. Biopsying a spinal cord lesion: A diagnostic dilemma. Case report and review of literature. Neurochirurgie 2018; 64:425-430. [PMID: 30243464 DOI: 10.1016/j.neuchi.2018.07.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Revised: 06/24/2018] [Accepted: 07/23/2018] [Indexed: 12/29/2022]
Abstract
Spinal cord biopsy is a difficult procedure fraught with the risk of false-negative results or even misdiagnosis in up to 30% of cases. Differential diagnoses of spinal cord lesions include a wide range of inflammatory, infectious and neoplastic diseases. Given the importance of correctly managing these pathologies, it is crucial to avoid delays in making the correct diagnosis in order to improve the patient's outcome. We present here the case of a 21-year-old male with rapidly progressing sphincter and lower limb motor dysfunctions up to complete paraplegia with evidence of thoracic spinal cord lesion on magnetic resonance imaging. None of the blood and cerebrospinal fluid tests pointed to a diagnosis, while a first spinal cord biopsy revealed an inflammatory necrotic process. After several weeks of empirical treatments and clinical stability, the patient started having focal structural seizures that became generalized with local progression of the lesion and diffuse leptomeningeal spread on magnetic resonance imaging. A second spinal cord biopsy found a grade IV glioblastoma with H3 K27M histone mutation. Unfortunately the patient passed away before any treatment could be initiated. In this report, the authors analyze the difficulty of making the rapid, correct diagnosis of a highly malignant intrinsic spinal cord lesion, discussing also possible strategies to avoid diagnostic delays and to improve the outcome of these difficult patients.
Collapse
Affiliation(s)
- L Dormegny
- Service de neurochirurgie, CHU de Strasbourg, hôpital de Hautepierre, 67000 Strasbourg, France.
| | - S Chibbaro
- Service de neurochirurgie, CHU de Strasbourg, hôpital de Hautepierre, 67000 Strasbourg, France
| | - M Ganau
- Service de neurochirurgie, CHU de Strasbourg, hôpital de Hautepierre, 67000 Strasbourg, France
| | - Mdn Santin
- Service de neurochirurgie, CHU de Strasbourg, hôpital de Hautepierre, 67000 Strasbourg, France
| | - L Kremer
- Service de neurologie, CHU de Strasbourg, hôpital de Hautepierre, 67000 Strasbourg, France
| | - F Proust
- Service de neurochirurgie, CHU de Strasbourg, hôpital de Hautepierre, 67000 Strasbourg, France
| |
Collapse
|
29
|
Clemens E, van der Kooi ALF, Broer L, van Dulmen-den Broeder E, Visscher H, Kremer L, Tissing W, Loonen J, Ronckers CM, Pluijm SMF, Neggers SJCMM, Zolk O, Langer T, Zehnhoff-Dinnesen AA, Wilson CL, Hudson MM, Carleton B, Laven JSE, Uitterlinden AG, van den Heuvel-Eibrink MM. The influence of genetic variation on late toxicities in childhood cancer survivors: A review. Crit Rev Oncol Hematol 2018; 126:154-167. [PMID: 29759558 DOI: 10.1016/j.critrevonc.2018.04.001] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2017] [Revised: 03/01/2018] [Accepted: 04/03/2018] [Indexed: 10/17/2022] Open
Abstract
INTRODUCTION The variability in late toxicities among childhood cancer survivors (CCS) is only partially explained by treatment and baseline patient characteristics. Inter-individual variability in the association between treatment exposure and risk of late toxicity suggests that genetic variation possibly modifies this association. We reviewed the available literature on genetic susceptibility of late toxicity after childhood cancer treatment related to components of metabolic syndrome, bone mineral density, gonadal impairment and hearing impairment. METHODS A systematic literature search was performed, using Embase, Cochrane Library, Google Scholar, MEDLINE, and Web of Science databases. Eligible publications included all English language reports of candidate gene studies and genome wide association studies (GWAS) that aimed to identify genetic risk factors associated with the four late toxicities, defined as toxicity present after end of treatment. RESULTS Twenty-seven articles were identified, including 26 candidate gene studies: metabolic syndrome (n = 6); BMD (n = 6); gonadal impairment (n = 2); hearing impairment (n = 12) and one GWAS (metabolic syndrome). Eighty percent of the genetic studies on late toxicity after childhood cancer had relatively small sample sizes (n < 200), leading to insufficient power, and lacked adjustment for multiple comparisons. Only four (4/26 = 15%) candidate gene studies had their findings validated in independent replication cohorts as part of their own report. CONCLUSION Genetic susceptibility associations are not consistent or not replicated and therefore, currently no evidence-based recommendations can be made for hearing impairment, gonadal impairment, bone mineral density impairment and metabolic syndrome in CCS. To advance knowledge related to genetic variation influencing late toxicities among CCS, future studies need adequate power, independent cohorts for replication, harmonization of disease outcomes and sample collections, and (international) collaboration.
Collapse
Affiliation(s)
- E Clemens
- Department of Pediatric Hematology and Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
| | - A L F van der Kooi
- Department of Pediatric Hematology and Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Gynecology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands
| | - L Broer
- Department of Internal Medicine, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands
| | | | - H Visscher
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Pediatrics, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Pediatrics, Antwerp University Hospital, Antwerp, Belgium
| | - L Kremer
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Pediatrics, Academic Medical Center - Emma Children's Hospital, Amsterdam, The Netherlands
| | - W Tissing
- Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - J Loonen
- Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - C M Ronckers
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Department of Pediatrics, Academic Medical Center - Emma Children's Hospital, Amsterdam, The Netherlands
| | - S M F Pluijm
- Department of Pediatric Hematology and Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - S J C M M Neggers
- Department of Pediatric Hematology and Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands; Department of Medicine, Section endocrinology, Erasmus MC, Rotterdam, The Netherlands
| | - O Zolk
- Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Hospital Ulm, Germany
| | - T Langer
- Pediatric Oncology, University Hospital for Children and Adolescents, Lübeck, Germany
| | | | - C L Wilson
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - M M Hudson
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - B Carleton
- BC Children's Hospital, Vancouver, Canada
| | - J S E Laven
- Department of Gynecology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands
| | - A G Uitterlinden
- Department of Internal Medicine, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands
| | | |
Collapse
|
30
|
Kremer L, Garcia-Sanz JA. Editorial: Is the Recent Burst of Therapeutic Anti-tumor Antibodies the Tip of an Iceberg? Front Immunol 2018; 9:442. [PMID: 29556241 PMCID: PMC5845095 DOI: 10.3389/fimmu.2018.00442] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Accepted: 02/19/2018] [Indexed: 11/13/2022] Open
Affiliation(s)
- Leonor Kremer
- Centro Nacional de Biotecnologia, Department of Immunology and Oncology, Spanish National Research Council (CSIC), Madrid, Spain
| | - Jose A Garcia-Sanz
- Cancer Genetics and Cancer Stem Cell Laboratory, Centro de Investigaciones Biologicas, Department of Molecular Biomedicine, Spanish National Research Council (CSIC), Madrid, Spain
| |
Collapse
|
31
|
Somovilla-Crespo B, Martín Monzón MT, Vela M, Corraliza-Gorjón I, Santamaria S, Garcia-Sanz JA, Kremer L. 92R Monoclonal Antibody Inhibits Human CCR9 + Leukemia Cells Growth in NSG Mice Xenografts. Front Immunol 2018; 9:77. [PMID: 29434597 PMCID: PMC5797297 DOI: 10.3389/fimmu.2018.00077] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Accepted: 01/11/2018] [Indexed: 12/19/2022] Open
Abstract
CCR9 is as an interesting target for the treatment of human CCR9+-T cell acute lymphoblastic leukemia, since its expression is limited to immature cells in the thymus, infiltrating leukocytes in the small intestine and a small fraction of mature circulating T lymphocytes. 92R, a new mouse mAb (IgG2a isotype), was raised using the A-isoform of hCCR9 as immunogen. Its initial characterization demonstrates that binds with high affinity to the CCR9 N-terminal domain, competing with the previously described 91R mAb for receptor binding. 92R inhibits human CCR9+ tumor growth in T and B-cell deficient Rag2−/− mice. In vitro assays suggested complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity as possible in vivo mechanisms of action. Unexpectedly, 92R strongly inhibited tumor growth also in a model with compromised NK and complement activities, suggesting that other mechanisms, including phagocytosis or apoptosis, might also be playing a role on 92R-mediated tumor elimination. Taken together, these data contribute to strengthen the hypothesis of the immune system’s opportunistic nature.
Collapse
Affiliation(s)
- Beatriz Somovilla-Crespo
- Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| | | | - Maria Vela
- Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| | - Isabel Corraliza-Gorjón
- Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| | - Silvia Santamaria
- Department of Cellular and Molecular Medicine, Centro de Investigaciones Biologicas (CIB-CSIC), Madrid, Spain
| | - Jose A Garcia-Sanz
- Department of Cellular and Molecular Medicine, Centro de Investigaciones Biologicas (CIB-CSIC), Madrid, Spain
| | - Leonor Kremer
- Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain.,Protein Tools Unit, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| |
Collapse
|
32
|
Pose-Utrilla J, García-Guerra L, Del Puerto A, Martín A, Jurado-Arjona J, De León-Reyes NS, Gamir-Morralla A, Sebastián-Serrano Á, García-Gallo M, Kremer L, Fielitz J, Ireson C, Pérez-Álvarez MJ, Ferrer I, Hernández F, Ávila J, Lasa M, Campanero MR, Iglesias T. Excitotoxic inactivation of constitutive oxidative stress detoxification pathway in neurons can be rescued by PKD1. Nat Commun 2017; 8:2275. [PMID: 29273751 PMCID: PMC5741635 DOI: 10.1038/s41467-017-02322-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Accepted: 11/20/2017] [Indexed: 11/26/2022] Open
Abstract
Excitotoxicity, a critical process in neurodegeneration, induces oxidative stress and neuronal death through mechanisms largely unknown. Since oxidative stress activates protein kinase D1 (PKD1) in tumor cells, we investigated the effect of excitotoxicity on neuronal PKD1 activity. Unexpectedly, we find that excitotoxicity provokes an early inactivation of PKD1 through a dephosphorylation-dependent mechanism mediated by protein phosphatase-1 (PP1) and dual specificity phosphatase-1 (DUSP1). This step turns off the IKK/NF-κB/SOD2 antioxidant pathway. Neuronal PKD1 inactivation by pharmacological inhibition or lentiviral silencing in vitro, or by genetic inactivation in neurons in vivo, strongly enhances excitotoxic neuronal death. In contrast, expression of an active dephosphorylation-resistant PKD1 mutant potentiates the IKK/NF-κB/SOD2 oxidative stress detoxification pathway and confers neuroprotection from in vitro and in vivo excitotoxicity. Our results indicate that PKD1 inactivation underlies excitotoxicity-induced neuronal death and suggest that PKD1 inactivation may be critical for the accumulation of oxidation-induced neuronal damage during aging and in neurodegenerative disorders. Excitotoxicity due to excessive glutamate release causes oxidative stress and neuronal death, and is a feature of many brain diseases. Here the authors show that protein kinase D1 is inactivated by excitotoxicity in a model of stroke and that its activation can be neuroprotective.
Collapse
Affiliation(s)
- Julia Pose-Utrilla
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain.,CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain
| | - Lucía García-Guerra
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain.,CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain
| | - Ana Del Puerto
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain.,CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain
| | - Abraham Martín
- Experimental Molecular Imaging (Molecular Imaging Unit), CIC biomaGUNE, Paseo Miramon, 182, 20009, San Sebastian, Spain
| | - Jerónimo Jurado-Arjona
- CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain.,Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), C/ Nicolas Cabrera 1, 28049, Madrid, Spain.,Institute of Physiological Chemistry, University Medical Center, Johannes Gutenberg University Mainz, Hanns-Dieter-Hüsch-Weg 19, 55128, Mainz, Germany
| | - Noelia S De León-Reyes
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain.,Centro Nacional de Biotecnología (CSIC), C/ Darwin 3, 28049, Madrid, Spain
| | - Andrea Gamir-Morralla
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain.,CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain.,Institute of Physiological Chemistry, University Medical Center, Johannes Gutenberg University Mainz, Hanns-Dieter-Hüsch-Weg 19, 55128, Mainz, Germany
| | - Álvaro Sebastián-Serrano
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain.,CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain
| | - Mónica García-Gallo
- Protein Tools Unit, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Científicas (CSIC), C/ Darwin 3, 28049, Madrid, Spain
| | - Leonor Kremer
- Protein Tools Unit, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Científicas (CSIC), C/ Darwin 3, 28049, Madrid, Spain
| | - Jens Fielitz
- Experimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin, Max-Delbrück-Center (MDC) for Molecular Medicine in the Helmholtz Association, Berlin, 13125, Germany.,Department of Cardiology, Heart Center Brandenburg and Medical University Brandenburg (MHB), Bernau, 16321, Germany
| | - Christofer Ireson
- Cancer Research Technology, London, EC1V 4AD, UK.,Pharmidex Pharmaceutical Services, 14 Hanover Street, London, W1S 1YH, UK
| | - Mª José Pérez-Álvarez
- CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain.,Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), C/ Nicolas Cabrera 1, 28049, Madrid, Spain.,Departamento de Biología (Unidad Docente Fisiología Animal), UAM, C/ Darwin 2, 28049, Madrid, Spain
| | - Isidro Ferrer
- CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain.,Instituto de Neuropatología, Hospital Universitario de Bellvitge, C/ Feixa LLarga s/n, 08907, Barcelona, Hospitalet de Llobregat, Spain
| | - Félix Hernández
- CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain.,Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), C/ Nicolas Cabrera 1, 28049, Madrid, Spain
| | - Jesús Ávila
- CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain.,Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), C/ Nicolas Cabrera 1, 28049, Madrid, Spain
| | - Marina Lasa
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain
| | - Miguel R Campanero
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain.,CIBERCV, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, 28029, Spain
| | - Teresa Iglesias
- Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), C/ Arturo Duperier 4, 28029, Madrid, Spain. .,CIBERNED, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, C/ Valderrebollo, 5, 28031, Madrid, Spain.
| |
Collapse
|
33
|
Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Front Immunol 2017; 8:1804. [PMID: 29312320 PMCID: PMC5742572 DOI: 10.3389/fimmu.2017.01804] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Accepted: 11/30/2017] [Indexed: 12/14/2022] Open
Abstract
Antibodies have proven their high value in antitumor therapy over the last two decades. They are currently being used as the first-choice to treat some of the most frequent metastatic cancers, like HER2+ breast cancers or colorectal cancers, currently treated with trastuzumab (Herceptin) and bevacizumab (Avastin), respectively. The impressive therapeutic success of antibodies inhibiting immune checkpoints has extended the use of therapeutic antibodies to previously unanticipated tumor types. These anti-immune checkpoint antibodies allowed the cure of patients devoid of other therapeutic options, through the recovery of the patient’s own immune response against the tumor. In this review, we describe how the antibody-based therapies will evolve, including the use of antibodies in combinations, their main characteristics, advantages, and how they could contribute to significantly increase the chances of success in cancer therapy. Indeed, novel combinations will consist of mixtures of antibodies against either different epitopes of the same molecule or different targets on the same tumor cell; bispecific or multispecific antibodies able of simultaneously binding tumor cells, immune cells or extracellular molecules; immunomodulatory antibodies; antibody-based molecules, including fusion proteins between a ligand or a receptor domain and the IgG Fab or Fc fragments; autologous or heterologous cells; and different formats of vaccines. Through complementary mechanisms of action, these combinations could contribute to elude the current limitations of a single antibody which recognizes only one particular epitope. These combinations may allow the simultaneous attack of the cancer cells by using the help of the own immune cells and exerting wider therapeutic effects, based on a more specific, fast, and robust response, trying to mimic the action of the immune system.
Collapse
Affiliation(s)
- Isabel Corraliza-Gorjón
- Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| | - Beatriz Somovilla-Crespo
- Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| | - Silvia Santamaria
- Department of Cellular and Molecular Medicine, Centro de Investigaciones Biologicas (CIB-CSIC), Madrid, Spain
| | - Jose A Garcia-Sanz
- Department of Cellular and Molecular Medicine, Centro de Investigaciones Biologicas (CIB-CSIC), Madrid, Spain
| | - Leonor Kremer
- Department of Immunology and Oncology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain
| |
Collapse
|
34
|
Santamaria S, Delgado M, Kremer L, Garcia-Sanz JA. Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible? Front Immunol 2017; 8:1509. [PMID: 29170667 PMCID: PMC5684111 DOI: 10.3389/fimmu.2017.01509] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Accepted: 10/25/2017] [Indexed: 12/12/2022] Open
Abstract
The cancer stem cell (CSC) hypothesis suggests that within a tumor, there is a small subpopulation of cells with stem cell properties responsible for tumor maintenance and metastasis generation. This hypothesis also implies that new antitumor drugs, rather than targeting the bulk of the tumor mass, would be more effective if they directly targeted the CSC subpopulation. The CSCs from several types of tumors have been identified with mAbs recognizing surface antigens in these cells; however, antigens specifically or exclusively expressed in the CSC population have not yet been identified. Thus, questioning the possibility of using therapeutic antibodies directed against the CSCs. Here, we review the possibilities of using antibodies directly targeting the CSCs as therapeutic agents in the form of naked antibodies, antibodies conjugated to nanoparticles, or antibody cocktails.
Collapse
Affiliation(s)
- Silvia Santamaria
- Cancer Genetics and Cancer Stem Cell Laboratory, Centro de Investigaciones Biologicas, Department of Cellular and Molecular Medicine, Spanish National Research Council (CSIC), Madrid, Spain
| | - Marisa Delgado
- Cancer Genetics and Cancer Stem Cell Laboratory, Centro de Investigaciones Biologicas, Department of Cellular and Molecular Medicine, Spanish National Research Council (CSIC), Madrid, Spain
| | - Leonor Kremer
- Centro Nacional de Biotecnologia, Department of Immunology and Oncology, Spanish National Research Council (CSIC), Madrid, Spain
| | - Jose A Garcia-Sanz
- Cancer Genetics and Cancer Stem Cell Laboratory, Centro de Investigaciones Biologicas, Department of Cellular and Molecular Medicine, Spanish National Research Council (CSIC), Madrid, Spain
| |
Collapse
|
35
|
Van Dijk I, Visser J, Wiersma J, Van Boggelen J, Balgobind B, Feijen L, Huijskens S, Kremer L, Rasch C, Bel A. EP-1379: Heart volume reduction in paediatric cancer patients during radiotherapy. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31814-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Velay A, Kack-Kack W, Abravanel F, Lhomme S, Leyendecker P, Kremer L, Chamouard P, Izopet J, Fafi-Kremer S, Barth H. Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient. J Neurovirol 2017; 23:615-620. [PMID: 28439773 DOI: 10.1007/s13365-017-0525-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Revised: 03/06/2017] [Accepted: 03/13/2017] [Indexed: 01/05/2023]
Abstract
Hepatitis E virus (HEV) infection is an emerging autochthonous disease in industrialized countries. Extra-hepatic manifestations, in particular neurologic manifestations, have been reported in HEV infection. Only a few cases of hepatitis E-associated Parsonage-Turner syndrome have been reported, and HEV genotypes were rarely determined. Here, we report the case of a Parsonage-Turner syndrome associated with an acute autochthonous HEV infection in a 55-year-old immunocompetent patient. HEV genomic RNA was detected in serum and cerebrospinal fluid samples (CSF), and molecular phylogenetic analysis of HEV was performed. The interest of this case lies in its detailed description notably the molecular analysis of HEV RNA isolated from serum and CSF. HEV infection should be considered in diagnostic investigations of neurologic manifestations associated with liver function perturbations.
Collapse
Affiliation(s)
- A Velay
- Virology Laboratory, University Hospital of Strasbourg, F-67000, Strasbourg, France. .,INSERM, IRM UMR-S 1109, F-67000, Strasbourg, France.
| | - W Kack-Kack
- Virology Laboratory, University Hospital of Strasbourg, F-67000, Strasbourg, France.,INSERM, IRM UMR-S 1109, F-67000, Strasbourg, France
| | - F Abravanel
- INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, F-31300, Toulouse, France.,CHU Toulouse Hôpital Purpan, Laboratoire de virologie, Institut fédératif de biologie de Purpan, F-31300, Toulouse, France
| | - S Lhomme
- INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, F-31300, Toulouse, France.,CHU Toulouse Hôpital Purpan, Laboratoire de virologie, Institut fédératif de biologie de Purpan, F-31300, Toulouse, France
| | - P Leyendecker
- Department of Neuroradiology, University Hospital of Strasbourg, F-67098, Strasbourg, France
| | - L Kremer
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Biopathologie de la Myéline, Neuroprotection et Stratégies Thérapeutiques, UMR_S INSERM U1119, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - P Chamouard
- Department of Gastroenterology and Hepatology, University Hospital of Strasbourg, F-67098, Strasbourg, France
| | - J Izopet
- INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, F-31300, Toulouse, France.,CHU Toulouse Hôpital Purpan, Laboratoire de virologie, Institut fédératif de biologie de Purpan, F-31300, Toulouse, France
| | - S Fafi-Kremer
- Virology Laboratory, University Hospital of Strasbourg, F-67000, Strasbourg, France.,INSERM, IRM UMR-S 1109, F-67000, Strasbourg, France
| | - H Barth
- Virology Laboratory, University Hospital of Strasbourg, F-67000, Strasbourg, France.,INSERM, IRM UMR-S 1109, F-67000, Strasbourg, France
| |
Collapse
|
37
|
Teepen J, Kok J, Van Leeuwen F, Tissing W, Dolsma W, Van der Pal H, Van Dulmen-den Broeder E, Van den Heuvel-Eibrink M, Loonen J, Bresters D, Versluys A, Neggers S, De Vries A, Jaspers M, Van den Berg M, Caron H, Van der Heiden-van der Loo M, Hollema N, Oldenburger F, Visser O, Overbeek L, Kremer L, Ronckers C. PO-0770: Subsequent colorectal adenomas in childhood cancer survivors: a DCOG LATER record linkage study. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32020-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Kok J, Teepen J, Van der Pal H, Dolsma W, Van Dulmen-den Broeder E, Van den Heuvel-Eibrink M, Loonen J, Tissing W, Bresters D, Versluys B, Neggers S, Van der Heiden-van der Loo M, Van Leeuwen F, Caron H, Oldenburger F, Janssens G, Maduro J, Tersteeg R, Van Rij C, Daniels L, Haasbeek C, Gijsbers-Bruggink A, Kremer L, Ronckers C. OC-0542: Benign tumours among long-term childhood cancer survivors: a DCOG LATER record linkage study. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31792-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Bartolini F, Andres-Delgado L, Qu X, Nik S, Ramalingam N, Kremer L, Alonso MA, Gundersen GG. An mDia1-INF2 formin activation cascade facilitated by IQGAP1 regulates stable microtubules in migrating cells. Mol Biol Cell 2016; 27:1797-808. [PMID: 27030671 PMCID: PMC4884070 DOI: 10.1091/mbc.e15-07-0489] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 03/25/2016] [Indexed: 01/08/2023] Open
Abstract
The formin INF2 is required for stable Glu microtubule formation and inhibition of microtubule dynamics in NIH3T3 cells downstream of mDia1 and LPA. Evidence also shows that the formation of an mDia1/INF2 complex is necessary for microtubule stabilization stimulated by LPA and is regulated by IQGAP1. Multiple formins regulate microtubule (MT) arrays, but whether they function individually or in a common pathway is unknown. Lysophosphatidic acid (LPA) stimulates the formation of stabilized detyrosinated MTs (Glu MTs) in NIH3T3 fibroblasts through RhoA and the formin mDia1. Here we show that another formin, INF2, is necessary for mDia1-mediated induction of Glu MTs and regulation of MT dynamics and that mDia1 can be bypassed by activating INF2. INF2 localized to MTs after LPA treatment in an mDia1-dependent manner, suggesting that mDia1 regulates INF2. Mutants of either formin that disrupt their interaction failed to rescue MT stability in cells depleted of the respective formin, and the mDia1-interacting protein IQGAP1 regulated INF2’s localization to MTs and the induction of Glu MTs by either formin. The N-terminus of IQGAP1 associated with the C-terminus of INF2 directly, suggesting the possibility of a tripartite complex stimulated by LPA. Supporting this, the interaction of mDia1 and INF2 was induced by LPA and dependent on IQGAP1. Our data highlight a unique mechanism of formin action in which mDia1 and INF2 function in series to stabilize MTs and point to IQGAP1 as a scaffold that facilitates the activation of one formin by another.
Collapse
Affiliation(s)
- Francesca Bartolini
- Department of Pathology and Cell Biology, Columbia University, New York, NY 10032
| | - Laura Andres-Delgado
- Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - Xiaoyi Qu
- Department of Pathology and Cell Biology, Columbia University, New York, NY 10032
| | - Sara Nik
- Department of Pathology and Cell Biology, Columbia University, New York, NY 10032
| | - Nagendran Ramalingam
- Department of Pathology and Cell Biology, Columbia University, New York, NY 10032
| | - Leonor Kremer
- Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - Miguel A Alonso
- Centro de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientificas and Universidad Autonoma de Madrid, 28049 Madrid, Spain
| | - Gregg G Gundersen
- Department of Pathology and Cell Biology, Columbia University, New York, NY 10032
| |
Collapse
|
40
|
Roncador G, Engel P, Maestre L, Anderson AP, Cordell JL, Cragg MS, Šerbec VČ, Jones M, Lisnic VJ, Kremer L, Li D, Koch-Nolte F, Pascual N, Rodríguez-Barbosa JI, Torensma R, Turley H, Pulford K, Banham AH. The European antibody network's practical guide to finding and validating suitable antibodies for research. MAbs 2015; 8:27-36. [PMID: 26418356 PMCID: PMC4966524 DOI: 10.1080/19420862.2015.1100787] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Antibodies are widely exploited as research/diagnostic tools and therapeutics. Despite providing exciting research opportunities, the multitude of available antibodies also offers a bewildering array of choice. Importantly, not all companies comply with the highest standards, and thus many reagents fail basic validation tests. The responsibility for antibodies being fit for purpose rests, surprisingly, with their user. This paper condenses the extensive experience of the European Monoclonal Antibody Network to help researchers identify antibodies specific for their target antigen. A stepwise strategy is provided for prioritising antibodies and making informed decisions regarding further essential validation requirements. Web-based antibody validation guides provide practical approaches for testing antibody activity and specificity. We aim to enable researchers with little or no prior experience of antibody characterization to understand how to determine the suitability of their antibody for its intended purpose, enabling both time and cost effective generation of high quality antibody-based data fit for publication.
Collapse
Affiliation(s)
- Giovanna Roncador
- a Monoclonal Antibody Unit; Spanish National Cancer Research Center ; Madrid , Spain
| | - Pablo Engel
- b Immunology Unit, Department of Cell Biology; Immunology and Neurosciences ; Medical School, University of Barcelona ; Spain
| | - Lorena Maestre
- a Monoclonal Antibody Unit; Spanish National Cancer Research Center ; Madrid , Spain
| | - Amanda P Anderson
- c NDCLS, Radcliffe Department of Medicine ; University of Oxford ; Oxford , UK
| | | | - Mark S Cragg
- e Antibody and Vaccine Group; Cancer Sciences Unit; University of Southampton; Faculty of Medicine; General Hospital , Southampton , UK
| | - Vladka Č Šerbec
- f Center for the Production of Diagnostic Reagents and for Research; Blood Transfusion Center of Slovenia ; Ljubljana , Slovenia
| | - Margaret Jones
- c NDCLS, Radcliffe Department of Medicine ; University of Oxford ; Oxford , UK
| | - Vanda J Lisnic
- g Center for Proteomics; Faculty of Medicine; University of Rijeka ; Rijeka , Croatia
| | - Leonor Kremer
- h Department of Immunology and Oncology ; Spanish National Center for Biotechnology; Consejo Superior de Investigaciones Científicas (CNB/CSIC) ; Madrid , Spain
| | - Demin Li
- c NDCLS, Radcliffe Department of Medicine ; University of Oxford ; Oxford , UK
| | | | - Núria Pascual
- j Custom Antibody Service (CAbS); IQAC-CSIC/CIBER-BBN ; Barcelona , Spain
| | | | - Ruurd Torensma
- l Department of Tumorimmunology ; Radboud University Medical Center ; Nijmegen , The Netherlands
| | - Helen Turley
- c NDCLS, Radcliffe Department of Medicine ; University of Oxford ; Oxford , UK
| | - Karen Pulford
- c NDCLS, Radcliffe Department of Medicine ; University of Oxford ; Oxford , UK
| | - Alison H Banham
- c NDCLS, Radcliffe Department of Medicine ; University of Oxford ; Oxford , UK
| |
Collapse
|
41
|
Vela M, Aris M, Llorente M, Garcia-Sanz JA, Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol 2015; 6:12. [PMID: 25688243 PMCID: PMC4311683 DOI: 10.3389/fimmu.2015.00012] [Citation(s) in RCA: 78] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 01/07/2015] [Indexed: 12/22/2022] Open
Abstract
The 1990s brought a burst of information regarding the structure, expression pattern, and role in leukocyte migration and adhesion of chemokines and their receptors. At that time, the FDA approved the first therapeutic antibodies for cancer treatment. A few years later, it was reported that the chemokine receptors CXCR4 and CCR7 were involved on directing metastases to liver, lung, bone marrow, or lymph nodes, and the over-expression of CCR4, CCR6, and CCR9 by certain tumors. The possibility of inhibiting the interaction of chemokine receptors present on the surface of tumor cells with their ligands emerged as a new therapeutic approach. Therefore, many research groups and companies began to develop small molecule antagonists and specific antibodies, aiming to neutralize signaling from these receptors. Despite great expectations, so far, only one anti-chemokine receptor antibody has been approved for its clinical use, mogamulizumab, an anti-CCR4 antibody, granted in Japan to treat refractory adult T-cell leukemia and lymphoma. Here, we review the main achievements obtained with anti-chemokine receptor antibodies for cancer immunotherapy, including discovery and clinical studies, proposed mechanisms of action, and therapeutic applications.
Collapse
Affiliation(s)
- Maria Vela
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB/CSIC), Madrid, Spain
| | - Mariana Aris
- Centro de Investigaciones Oncológicas, Fundación Cáncer, Buenos Aires, Argentina
| | - Mercedes Llorente
- Protein Tools Unit, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB/CSIC), Madrid, Spain
| | - Jose A. Garcia-Sanz
- Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CIB/CSIC), Madrid, Spain
| | - Leonor Kremer
- Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB/CSIC), Madrid, Spain
- Protein Tools Unit, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CNB/CSIC), Madrid, Spain
| |
Collapse
|
42
|
Singh S, Bouzinbi N, Chaturvedi V, Godreuil S, Kremer L. In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infect 2014; 20:O1124-7. [DOI: 10.1111/1469-0691.12780] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Accepted: 08/13/2014] [Indexed: 11/28/2022]
|
43
|
Barbarroja-Escudero J, Prieto-Martin A, Monserrat-Sanz J, Reyes-Martin E, Diaz-Martin D, Antolin-Amerigo D, Rodriguez-Rodriguez M, Canseco-Gonzalez F, Kremer L, Martinez-A C, Alvarez-Mon M. Abnormal chemokine receptor profile on circulating T lymphocytes from nonallergic asthma patients. Int Arch Allergy Immunol 2014; 164:228-36. [PMID: 25178112 DOI: 10.1159/000365627] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Accepted: 06/27/2014] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND T lymphocytes are involved in the pathogenesis of nonallergic asthma. The objective of this study was to characterize the subset distribution and pattern of chemokine receptor expression in circulating T lymphocyte subsets from nonallergic asthma patients. METHODS Forty stable nonallergic asthma patients and 16 sex- and age-matched healthy donors were studied. Twelve patients did not receive inhaled steroids (untreated patients), 16 received 50-500 μg b.i.d. of inhaled fluticasone propionate (FP) (standard-dose patients), and 12 received over 500 μg b.i.d. of inhaled FP (high-dose patients) for at least 12 months prior to the beginning of this study and were clinically well controlled. Flow cytometry was performed using a panel of monoclonal antibodies (4 colors). RESULTS Nonallergic asthma patients treated with high doses of inhaled FP showed a significant reduction in the percentages of CD3+ T lymphocytes compared to healthy controls. Untreated patients showed a significant increase in CCR6 expression in CD8+CD25+ and CD8+CD25+bright T cells compared to healthy controls. The results were similar for CXCR3 and CCR5 expression. In patients treated with standard doses of FP, CCR5 expression was significantly increased in CD3+ T lymphocytes relative to healthy controls. CONCLUSIONS The different groups of clinically stable nonallergic asthmatic patients showed distinct patterns of alterations in subset distribution as well as CCR6, CXCR3, and CCR5 expression on circulating T lymphocytes. .
Collapse
|
44
|
Chamorro S, Vela M, Franco-Villanueva A, Carramolino L, Gutiérrez J, Gómez L, Lozano M, Salvador B, García-Gallo M, Martínez-A C, Kremer L. Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts. MAbs 2014; 6:1000-12. [PMID: 24870448 PMCID: PMC4171004 DOI: 10.4161/mabs.29063] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Tumor expression of certain chemokine receptors is associated with resistance to apoptosis, migration, invasiveness and metastasis. Because CCR9 chemokine receptor expression is very restricted in healthy tissue, whereas it is present in tumors of distinct origins including leukemias, melanomas, prostate and ovary carcinomas, it can be considered a suitable candidate for target-directed therapy. Here, we report the generation and characterization of 91R, a mouse anti-human CCR9 IgG2b monoclonal antibody that recognizes an epitope within the CCR9 N-terminal domain. This antibody inhibits the growth of subcutaneous xenografts from human acute T lymphoblastic leukemia MOLT-4 cells in immunodeficient Rag2−/− mice. Tumor size in 91R-treated mice was reduced by 85% compared with isotype-matched antibody-treated controls. Tumor reduction in 91R-treated mice was concomitant with an increase in the apoptotic cell fraction and tumor necrotic areas, as well as a decrease in the fraction of proliferating cells and in tumor vascularization. In the presence of complement or murine natural killer cells, 91R promoted in vitro lysis of MOLT-4 leukemia cells, indicating that this antibody might eliminate tumor cells via complement- and cell-dependent cytotoxicity. The results show the potential of the 91R monoclonal antibody as a therapeutic agent for treatment of CCR9-expressing tumors.
Collapse
Affiliation(s)
- Sonia Chamorro
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - Maria Vela
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - Ana Franco-Villanueva
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - Laura Carramolino
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain; Current Affiliation: Centro Nacional de Investigaciones Cardiovasculares; Instituto de Salud Carlos III (CNIC/ISCIII); Madrid, Spain
| | - Julio Gutiérrez
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - Lucio Gómez
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain; Protein Tools Unit; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - María Lozano
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain; Protein Tools Unit; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - Beatriz Salvador
- Department of Plant Molecular Genetics; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - Mónica García-Gallo
- Protein Tools Unit; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - Carlos Martínez-A
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| | - Leonor Kremer
- Department of Immunology and Oncology; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain; Protein Tools Unit; Centro Nacional de Biotecnología; Consejo Superior de Investigaciones Científicas (CNB/CSIC); Madrid, Spain
| |
Collapse
|
45
|
Balzer K, Kremer L, Junghans A, Halfens R, Dassen T, Kottner J. What patient characteristics guide nurses’ clinical judgement on pressure ulcer risk? A mixed methods study. Int J Nurs Stud 2014; 51:703-16. [DOI: 10.1016/j.ijnurstu.2013.09.005] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2013] [Revised: 08/27/2013] [Accepted: 09/13/2013] [Indexed: 11/26/2022]
|
46
|
Kremer L, Slassi Sennou I, Benkirane N, Araqi Houssaini A, Collongues N, Javier RM, De Seze J. Évaluation du taux de 25-hydroxy-vitamine D dans la neuromyélite optique. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
47
|
Kremer L, Brun S, Beaino W, Taleb O, Lam D, Trifilieff E, De Seze J. Validation et caractérisation d’un modèle murin de polyradiculonévrite chronique. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
48
|
Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 2013; 20:843-7. [PMID: 24099751 DOI: 10.1177/1352458513507822] [Citation(s) in RCA: 131] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Accepted: 09/13/2013] [Indexed: 12/17/2022]
Abstract
BACKGROUND Neuromyelitis optica (NMO) is a severe autoimmune disease of the central nervous system characterized by spinal cord and optic nerve involvement. Brainstem manifestations have recently been described. OBJECTIVE To evaluate the time of occurrence, the frequency and the characteristics of brainstem symptoms in a cohort of patients with NMO according to the ethnic background and the serologic status for anti-aquaporin-4 antibodies (AQP4-abs). METHODS We performed a multicenter study of 258 patients with NMO according to the 2006 Wingerchuk criteria and we evaluated prospectively the frequency, the date of onset and the duration of various brainstem signs in this population. RESULTS Brainstem signs were observed in 81 patients (31.4%). The most frequently observed signs were vomiting (33.1%), hiccups (22.3%), oculomotor dysfunction (19.8%), pruritus (12.4%), followed by hearing loss (2.5%), facial palsy (2.5%), vertigo or vestibular ataxia (1.7%), trigeminal neuralgia (2.5%) and other cranial nerve signs (3.3%). They were inaugural in 44 patients (54.3%). The prevalence was higher in the non-Caucasian population (36.6%) than in the Caucasian population (26%) (p<0.05) and was higher in AQP4-ab-seropositive patients (32.7%) than in seronegative patients (26%) (not significant). CONCLUSIONS This study confirms the high frequency of brainstem symptoms in NMO with a majority of vomiting and hiccups. The prevalence of these manifestations was higher in the non Caucasian population.
Collapse
Affiliation(s)
- L Kremer
- Department of Neurology, University Hospital of Strasbourg, France
| | - M Mealy
- Department of Neurology, John Hopkins University, USA
| | - A Jacob
- The Walton Centre for Neurology and Neurosurgery, UK
| | - I Nakashima
- Department of Neurology, Tohoku University, Japan
| | - P Cabre
- Department of Neurology, Centre Hospitalier La Meynard, France
| | - S Bigi
- Division of Neurology, The Hospital for Sick Children, Toronto, Canada
| | - F Paul
- Department of Neurology and NeuroCure Clinical Research Center, Charité University Medicine, Germany
| | - S Jarius
- Department of Neurology, University of Heidelberg, Germany
| | - O Aktas
- Department of Neurology, Heinrich-Heine University, Germany
| | - L Elsone
- The Walton Centre for Neurology and Neurosurgery, UK
| | - K Mutch
- The Walton Centre for Neurology and Neurosurgery, UK
| | - M Levy
- Department of Neurology, John Hopkins University, USA
| | - Y Takai
- Department of Neurology, Tohoku University, Japan
| | - N Collongues
- Department of Neurology, University Hospital of Strasbourg, France
| | - B Banwell
- Division of Neurology, The Hospital for Sick Children, Toronto, Canada
| | - K Fujihara
- Department of Neurology, Tohoku University, Japan
| | - J de Seze
- Department of Neurology, University Hospital of Strasbourg, France
| |
Collapse
|
49
|
Kremer L, Keller A, Sabau-Philippi S, Bataillard M, Wolff V. Polyangéite microscopique révélée par des hématomes cérébraux à répétition. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
50
|
Aranda JF, Reglero-Real N, Marcos-Ramiro B, Ruiz-Sáenz A, Fernández-Martín L, Bernabé-Rubio M, Kremer L, Ridley AJ, Correas I, Alonso MA, Millán J. MYADM controls endothelial barrier function through ERM-dependent regulation of ICAM-1 expression. Mol Biol Cell 2013; 24:483-94. [PMID: 23264465 PMCID: PMC3571871 DOI: 10.1091/mbc.e11-11-0914] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Revised: 11/15/2012] [Accepted: 12/14/2012] [Indexed: 11/18/2022] Open
Abstract
The endothelium maintains a barrier between blood and tissue that becomes more permeable during inflammation. Membrane rafts are ordered assemblies of cholesterol, glycolipids, and proteins that modulate proinflammatory cell signaling and barrier function. In epithelial cells, the MAL family members MAL, MAL2, and myeloid-associated differentiation marker (MYADM) regulate the function and dynamics of ordered membrane domains. We analyzed the expression of these three proteins in human endothelial cells and found that only MYADM is expressed. MYADM was confined in ordered domains at the plasma membrane, where it partially colocalized with filamentous actin and cell-cell junctions. Small interfering RNA (siRNA)-mediated MYADM knockdown increased permeability, ICAM-1 expression, and leukocyte adhesion, all of which are features of an inflammatory response. Barrier function decrease in MYADM-silenced cells was dependent on ICAM-1 expression. Membrane domains and the underlying actin cytoskeleton can regulate each other and are connected by ezrin, radixin, and moesin (ERM) proteins. In endothelial cells, MYADM knockdown induced ERM activation. Triple-ERM knockdown partially inhibited ICAM-1 increase induced by MYADM siRNA. Importantly, ERM knockdown also reduced ICAM-1 expression in response to the proinflammatory cytokine tumor necrosis factor-α. MYADM therefore regulates the connection between the plasma membrane and the cortical cytoskeleton and so can control the endothelial inflammatory response.
Collapse
Affiliation(s)
- Juan F. Aranda
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | - Natalia Reglero-Real
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | - Beatriz Marcos-Ramiro
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | - Ana Ruiz-Sáenz
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | - Laura Fernández-Martín
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | - Miguel Bernabé-Rubio
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | - Leonor Kremer
- Centro Nacional de Biotecnología. Consejo Superior de Investigaciones Científicas, Cantoblanco, 28049 Madrid, Spain
| | - Anne J. Ridley
- Randall Division of Cell and Molecular Biophysics, King's College London, London SE1 1UL, United Kingdom
| | - Isabel Correas
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | - Miguel A. Alonso
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| | - Jaime Millán
- Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas and Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
| |
Collapse
|